JP2024510142A5 - - Google Patents
Info
- Publication number
- JP2024510142A5 JP2024510142A5 JP2023553957A JP2023553957A JP2024510142A5 JP 2024510142 A5 JP2024510142 A5 JP 2024510142A5 JP 2023553957 A JP2023553957 A JP 2023553957A JP 2023553957 A JP2023553957 A JP 2023553957A JP 2024510142 A5 JP2024510142 A5 JP 2024510142A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163156320P | 2021-03-03 | 2021-03-03 | |
| US63/156,320 | 2021-03-03 | ||
| PCT/US2022/018737 WO2022187510A1 (en) | 2021-03-03 | 2022-03-03 | Methods for the treatment of thyroid eye disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024510142A JP2024510142A (ja) | 2024-03-06 |
| JP2024510142A5 true JP2024510142A5 (https=) | 2025-03-11 |
Family
ID=83154512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023553957A Pending JP2024510142A (ja) | 2021-03-03 | 2022-03-03 | 甲状腺眼症の処置のための方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240158516A1 (https=) |
| EP (1) | EP4301410A4 (https=) |
| JP (1) | JP2024510142A (https=) |
| CN (1) | CN117813114A (https=) |
| AR (1) | AR125589A1 (https=) |
| AU (1) | AU2022230416A1 (https=) |
| BR (1) | BR112023017797A2 (https=) |
| CA (1) | CA3210855A1 (https=) |
| CO (1) | CO2023012639A2 (https=) |
| MX (1) | MX2023010278A (https=) |
| TW (1) | TW202246339A (https=) |
| WO (1) | WO2022187510A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220267450A1 (en) | 2020-10-14 | 2022-08-25 | Viridian Therapeutics, Inc. | Compositions and methods for treatment of thyroid eye disease |
| EP4384219A4 (en) | 2021-08-10 | 2025-06-18 | Viridian Therapeutics, Inc. | COMPOSITIONS, DOSAGES AND METHODS FOR THE TREATMENT OF THYROID EYE DISEASE |
| US20230406942A1 (en) * | 2022-06-10 | 2023-12-21 | Horizon Therapeutics Ireland Dac | Igf1r antibodies |
| WO2024069236A1 (en) * | 2022-09-30 | 2024-04-04 | Horizon Therapeutics Ireland Dac | Methods for treating inactive or chronic thyroid eye disease |
| AU2024287547A1 (en) * | 2023-07-07 | 2026-01-22 | Viridian Therapeutics, Inc. | Methods of treating chronic thyroid eye disease |
| WO2026055673A1 (en) * | 2024-09-09 | 2026-03-12 | Viridian Therapeutics, Inc. | Methods for treatment of thyroid eye disease with an anti-igf-1r antibody |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3146469B2 (ja) * | 1993-09-03 | 2001-03-19 | 株式会社ニッショー | 自動注射器 |
| US7538195B2 (en) * | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| US8367805B2 (en) * | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| MX2013008833A (es) * | 2011-02-02 | 2013-12-06 | Amgen Inc | Metodos y composiciones relacionadas con la inhibicion de receptor del factor de crecimiento similar a la insulina 1 (igf-1r). |
| MX364861B (es) * | 2013-04-29 | 2019-05-09 | Hoffmann La Roche | Anticuerpos anti-receptor del factor de crecimiento de tipo insulinico humano 1 (anti-igf-1r) con abolicion de la union al fcrn y su uso en el tratamiento de enfermedades oculares vasculares. |
| HRP20260151T1 (hr) * | 2016-08-02 | 2026-03-27 | Visterra, Inc. | Modificirani polipeptidi i njihova uporaba |
-
2022
- 2022-02-25 TW TW111107147A patent/TW202246339A/zh unknown
- 2022-03-02 AR ARP220100468A patent/AR125589A1/es unknown
- 2022-03-03 US US18/548,484 patent/US20240158516A1/en active Pending
- 2022-03-03 MX MX2023010278A patent/MX2023010278A/es unknown
- 2022-03-03 EP EP22764068.7A patent/EP4301410A4/en active Pending
- 2022-03-03 AU AU2022230416A patent/AU2022230416A1/en active Pending
- 2022-03-03 BR BR112023017797A patent/BR112023017797A2/pt not_active Application Discontinuation
- 2022-03-03 CN CN202280031787.0A patent/CN117813114A/zh active Pending
- 2022-03-03 CA CA3210855A patent/CA3210855A1/en active Pending
- 2022-03-03 JP JP2023553957A patent/JP2024510142A/ja active Pending
- 2022-03-03 WO PCT/US2022/018737 patent/WO2022187510A1/en not_active Ceased
-
2023
- 2023-09-25 CO CONC2023/0012639A patent/CO2023012639A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024510142A5 (https=) | ||
| KR102412023B1 (ko) | 레날리도마이드 또는 포말리도마이드 및 ｃｄ38 항체-감쇠 인터페론-알파 구성체의 조합, 및 이의 용도 | |
| JP7237848B2 (ja) | 免疫原性の低下のための方法及び組成物 | |
| CN112105343A (zh) | 抗-pd-1抗体组合物 | |
| EA031436B1 (ru) | Водная фармацевтическая композиция, содержащий ее предварительно заполненный шприц и применение композиции в лечении аутоиммунных заболеваний | |
| CN107073113A (zh) | 抗il‑7r抗体组合物 | |
| US12421317B2 (en) | Polynucleotides encoding anti-glucagon-like peptide 1 receptor (GLP1R) antagonist antibodies | |
| WO2023006055A1 (en) | Anti-pd-1 antibody pharmaceutical composition and use thereof | |
| JP2025501028A5 (https=) | ||
| AU2021211795A1 (en) | Pharmaceutical composition containing anti-BTLA antibody and use thereof | |
| JP2025503339A5 (https=) | ||
| JP2025503614A5 (https=) | ||
| TW202342095A (zh) | 用於治療和預防ｃｏｖｉｄ—１９之組成物 | |
| WO2023198116A1 (en) | Stable high concentration arginine formulations containing pd-1 antibody and methods of use thereof | |
| JP2025519612A (ja) | Ｉｇｆ１ｒ抗体 | |
| CN114786717A (zh) | 稳定的水性抗-tfpi抗体制剂 | |
| WO2021018191A1 (zh) | Il-17拮抗剂治疗自身免疫疾病的方法 | |
| CA3172471C (en) | Anti-glp1r antagonist antibodies and methods of use thereof | |
| WO2026026893A1 (zh) | 结合人gprc5d/bcma/cd3的三特异性抗体制剂及其用途 | |
| HK40075201B (zh) | 稳定的水性抗-tfpi抗体制剂 | |
| HK40075201A (en) | Stable aqueous anti-tfpi antibody formulation | |
| HK1239517A1 (en) | Anti-il-7r antibody compositions | |
| EA043164B1 (ru) | Способы и композиции для снижения иммуногенности | |
| HK1235070A1 (en) | Combination of lenalidomide and polypeptide construct, and uses thereof | |
| HK1235070B (en) | Combination of lenalidomide and polypeptide construct, and uses thereof |